Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AES Corp (AES) vs BridgeBio Pharma Inc (BBIO) Price & Performance

BridgeBio Pharma IncTrade

Price performance (Past 24H)

Key statistics

AES Corp vs BridgeBio Pharma Inc — how do they compare? AES Corp trades at $14.73 (market cap $10.49B), while BridgeBio Pharma Inc trades at $84.58 (market cap $16.36B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap, and AES Corp pays a 4.79% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.

AESBBIO
Market Cap
$10.49B$16.36B
Sector
UtilitiesHealth
52-Week High
$17.28$90.17
52-Week Low
$12.51$47.29
Enterprise Value
$40.75B$18.14B
Dividend Yield
4.79%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AES Corp

AES trades at $14.73, down slightly by 0.03%, with a bearish technical signal from moving averages but neutral oscillators. The company shows strong profitability with a 14.34% net income margin and 45.05% ROE, supported by recent earnings beats. A pending $33.4 billion acquisition by a consortium led by Global Infrastructure Partners and EQT, approved by stockholders in June 2026, dominates recent news, alongside a quarterly dividend of $0.18 per share.

The outlook is heavily influenced by the acquisition, offering a near-term upside to the $15 buyout price, but regulatory and shareholder approval risks remain. Long-term fundamentals are solid with projected revenue growth to $13.1 billion in 2026, though high debt levels and integration challenges post-acquisition pose risks. Analyst sentiment is mixed with a buy consensus of 43%.

BridgeBio Pharma Inc

BridgeBio Pharma (BBIO) trades at $84.57, down slightly by 0.12% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth driven by Attruby sales, though it missed EPS estimates. With a high P/S ratio of 22.77 and negative profitability metrics, the stock is priced for future growth, supported by strong analyst buy ratings and a $104.56 consensus price target.

The outlook hinges on successful product launches and regulatory approvals, with three potential launches expected within 12 months offering significant upside. Key risks include persistent cash burn, high debt, and execution challenges in bringing new treatments to market, which could pressure the stock if milestones are missed.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AES Corp

AES is a global power company operating across 14 countries and 4 continents. Its current generation portfolio as of year-end 2021 consists of over 31 gigawatts of generation, with the generation mix composed of renewables (43%), gas (32%), coal (23%), and oil (2%). The company has 3.5 gigawatts of generation under construction. AES has majority ownership and operates six electric utilities distributing power to 2.6 million customers.

Read more on AES

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO